Annual Report 2019

We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

Read more

The REQUEST study is now published

The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

Read more

Investor Presentation, March 3

Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this…

Read more

MiraQ approved for sale in Canada

MiraQ™ is Medistim's newest generation of products for quality assurance within  vascular and cardiac surgery. The system is based on ultrasound, and combines quantitative blood flow volume through transit time flow measurement (TTFM)  with morphological…

Read more

Results for the Third Quarter 2019

Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 %  growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…

Read more

Results for the First Quarter 2019

Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…

Read more

Annual Report 2018

During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…

Read more